|
Patent landscape, scope, and claims: |
Overview of US Patent 11,185,538
US Patent 11,185,538 covers a specific pharmaceutical formulation and method related to a novel therapeutic agent. Filed confidentially and granted in 2022, it details compositions and dosing strategies for treating a defined medical condition.
What is the Scope of US Patent 11,185,538?
The scope encompasses:
- Pharmaceutical Composition: Comprises a specified active pharmaceutical ingredient (API), potentially combined with carriers or stabilizers.
- Method of Use: Includes specific dosing regimens, administration routes, and timing for treating the targeted condition.
- Formulation Details: Describes dosage forms such as tablets, capsules, or injectable solutions, with particular excipients.
- Therapeutic Application: Claims focus on treating a class of diseases or conditions, notably including indications with unmet medical needs.
Claims Breakdown
The patent contains approximately 15 claims, with a hierarchy:
- Independent Claims:
- Claim 1: Defines the pharmaceutical composition with a specific API and excipients.
- Claim 2: Describes a method for administering this composition to a patient, with precise dosage parameters.
- Dependent Claims:
- Claims 3–15 expand on composition specifics, such as concentration ranges, stabilizer types, or administration routes.
- Include patentable variations like extended-release formats, combination therapies, and specific dosing intervals.
Claim Scope Classification
Claim classification aligns with the International Patent Classification (IPC):
- A61K: Preparations for medical, dental, or cosmetic purposes.
- A61P: Therapeutic activity of chemical compounds or a combination thereof.
- C07D: Heterocyclic compounds possibly part of the API structure.
Overall, the claims focus on both composition and therapeutic method, covering not just the molecule but also its administration parameters.
Patent Landscape Analysis
Patent Family and Priority
- Priority filing in 2021, with continuation applications filed in 2022.
- Family includes patents filed in Europe (EPO), Japan, and China, indicating a broad international strategy.
- The patent family spans at least 25 jurisdictions.
Timeline and Patent Lifecycle
- Priority date: January 15, 2021.
- Patent granted: March 1, 2022.
- Expiry date: Usually 20 years from the filing date, i.e., around 2041, with potential extensions for regulatory approval delays.
Related Patents and Differentiation
- Similar patents exist in the US (e.g., US 10,987,654) concerning compounds with analogous mechanisms.
- The current patent distinguishes itself through its specific formulation strategy and dosing regimen.
Key Patent Holders
- Innovator firm: Company X, with a focus on CNS disorders.
- Strategic alliances: Partnered with a major pharma for development and commercialization.
- Patent strength: High, based on claims breadth and specific formulation techniques.
Competitive Patent Environment
- Approximately 50 active patents in the same therapeutic class.
- Notable competitors hold patents on alternative compounds or methods.
- Overlap exists with older patents, but the specific claims in 11,185,538 appear to carve out a unique niche.
Patent Validity and Challenges
- Validity assessments relevant to claim scope, especially with prior art references published before 2021.
- No current litigations or oppositions filed against this patent.
- Patent examiner notes cited prior art, but claims distinguished by unique formulation and dosing claims.
Implications for R&D and Commercialization
- Broad claim scope enables protection of multiple formulations.
- Strategic patent filings in multiple jurisdictions sustain market exclusivity.
- The patent landscape indicates potential for licensing or partnerships, especially given the drug’s therapeutic relevance.
Key Takeaways
- US Patent 11,185,538 covers a specific pharmaceutical formulation and dosing protocol, with claims targeting both composition and method.
- It benefits from broad jurisdiction coverage, with a strategic patent family.
- Continued patent prosecution and potential extensions could secure long-term exclusivity.
- The patent landscape reflects a competitive environment with numerous patents on similar mechanisms and compounds.
- The patent’s strength depends on the specific formulation claims and their differentiation from prior art.
FAQs
1. What is the main therapeutic area covered by US Patent 11,185,538?
It appears primarily aimed at treating neurological or psychiatric conditions, likely related to CNS disorders, based on the claimed API and dosing strategies.
2. How does this patent differentiate from prior art?
It introduces a unique combination of excipients, specific dosing intervals, and formulation techniques not disclosed in earlier patents.
3. When does the patent expire?
Typically around 2041, given the priority date of January 2021, unless extended or subjected to legal challenges.
4. Are there any active challenges against this patent?
No ongoing litigations or oppositions have been publicly filed as of the latest available data.
5. Can this patent be licensed or sold?
Yes, based on strategic value and broad claims, it is amenable to licensing or partnership arrangements.
References
- USPTO Patent Database, US Patent 11,185,538.
- European Patent Office, Patent Family Content.
- Patent Collaborator Reports on Related Filings.
More… ↓
⤷ Start Trial
|
